Pharmacist Resources

THALOMID® (thalidomide) in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM).

THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).

THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis.

THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.

THALOMID REMS® information for certified pharmacies

THALOMID is only dispensed from THALOMID REMS® program certified pharmacies.

As a THALOMID REMS® certified pharmacy, you must follow the requirements of the THALOMID REMS® program. You may download a guide to the program, a checklist for counseling patients, and the full prescribing information below.


The Celgene REMS Pharmacy Portal

In addition to calling the Celgene Customer Care Center to obtain a confirmation number for a prescription,
eligible pharmacies can obtain confirmation numbers using the Celgene REMS Pharmacy Portal at CelgeneREMSPharmacyPortal.com. Contact your Celgene Account Manager to see if your pharmacy
is eligible.


Please report adverse drug experiences that are suspected to be associated with the use of THALOMID
and any suspected pregnancy occurring during the treatment with THALOMID to Celgene using any of the
following methods:

REPORTING TO CELGENE

Online:

Email:

Telephone:

1-908-673-9667

Toll-free:

1-800-640-7854 (Global Drug Safety & Risk Management) or
1-888-423-5436 (Celgene Customer Care Center)

Fax:

1-908-673-9115

Mail to:

Global Drug Safety & Risk Management
Celgene Corporation
86 Morris Avenue
Summit, New Jersey 07901

Other:

Per individual agreement between the reporting organization and Celgene Global Drug Safety & Risk Management

REPORTING TO THE FDA

Adverse drug experiences that are suspected to be associated with the use of THALOMID and
any suspected pregnancy occurring during the treatment with THALOMID may also be reported
to the FDA MedWatch Reporting System using any of the following methods:

Online:

Telephone:

1-800-FDA-1088

Fax:

1-800-FDA-0178

Mail to:

MedWatch
5600 Fishers Lane
Rockville, MD 20852-9787

For additional information about the THALOMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Download the
Celgene REMS mobile app
for CelgeneRiskManagement.com
to your iPad here: